Primary Hyperparathyroidism overlapping with Multiple Sclerosis: a catastrophic marriage


Gianfranco Cervellin
Vincenzo Brianti
Lorenzo Viani
Lucia Feldmann
Gianni Rastelli


hyperparathyroidism; multiple sclerosis; hypercalcemia; demyelinating disease; fatigue


Primary hyperparathyroidism (PHPT) often leads to neurological or psychiatric disorders, thus mimicking different diseases. Here we present a 77-years old man visited in the Emergency Department complaining for fatigue, multiple falls, nausea, anorexia, and constipation. Symptoms were rapidly worsening, and on admission he appeared sleepy, responsive to verbal stimulus, disoriented, dehydrated, unable to maintain upright position. He suffered from mild, relapsing and remitting Multiple Sclerosis (MS) since the age of 45, at that moment not requiring treatment. The laboratory tests displayed severe hypercalcemia (16.8 mg/dL), slightly decreased level of serum phosphorus (2.8 mg/dL), very high levels of parathyroid hormone (PTH) (508 pg/mL). A parathyroid mass (35x21x32 mm) in left paratracheal position was found with Computed Tomography (CT) of the neck. After correcting hypercalcemia, he was operated on day 18, thus confirming the parathyroid adenoma, that was successfully removed. One month later, the patient was completely well, and able to walk without any help, like three months before. The lab tests’ values obtained during the control visit showed complete normalization of calcium-phosphate metabolism. Diabetes, too, was going better, allowing a reduction in metformin dosage. At the best of our knowledge this is the first described case of a clinically significant overlapping between symptoms due to a long-lasting mild MS and an unrecognized, severe, PHPT. This case underlines the importance of a thorough metabolic evaluation of each patient presenting worsening of his neuromuscular and/or neuropsychiatric condition, even when previously known to be affected by a defined neurologic or psychiatric disease.



Download data is not yet available.
Abstract 1 |


1. Patten BM, Bilezikian JP, Mallette LE, et al. Neuromuscular disease in primary hyperparathyroidism. Ann Intern Med 1974;80:182-193
2. Carnevale V, Minisola S, Romagnoli E, et al. Concurrent improvement of neuromuscular and skeletal involvement following surgery for primary hyperparathyroidism. J Neurol 1992;239:57
3. Patten BM, Pages M. Severe neurological disease associated with hyperparathyroidism. Ann Neurol 1984;15:453-456
4. Ghosh M, Bhattacharya A, Ghosh K, et al. A commonly overlooked motor neuron disease mimicker. Endocrinol Diabetes Metab Case Reports 2014:14-17
5. Siqueira Carvalho AA, Vieira A, Simplício H, et al. Primary hyperparathyroidism simulating motor neuron disease: Case report. Arq Neuropsiquiatr 2005;63:160-162
6. De Rosa A, Rinaldi C, Tucci T, et al. Co-existence of primary hyperparathyroidism and Parkinson’s disease in three patients: an incidental finding? Parkinsonism Relat Disord. 2011;17:771-773
7. Hirooka Y, Yuasa K, Hibi K, et al. Hyperparathyroidism associated with parkinsonism. Internal Medicine 1992;31:904-907
8. Guimaraes Augusto CM, Sobral de Morais N, Palmeira Santana R et al. Parkinsonism as an atypical manifestation of primary hypoerparathyroidism. AACE Clinical Case Report 2019;5:e244-e246
9. Singh P, Bauernfreund Y, Arya P, Singh E, Shute J. Primary hyperparathyroidism presenting as acute psychosis secondary to hypercalcaemia requiring curative parathyroidectomy. J Surg Case Rep. 2018;2018:rjy023
10. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. J Clin Endocrinol Metab. 2014;99:3561-3569
11. Bilezikian JP, Silverberg SJ, Bandeira F, et al. Management of Primary Hyperparathyroidism. J Bone Mirer Res 2022;37:2391-2403
12. Patti F, Vila C. Symptoms, Prevalence and Impact of Multiple Sclerosis in Younger Patients: A Multinational Survey. Neuroepidemiology 2014; 42:211–218
13. Braley TJ, Chervin RD. Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep. 2010;33:1061–1067
14. Mills RJ, Young CA. A medical definition of fatigue in multiple sclerosis. QJM. 2008;101:49–60
15. Vucic S, Burke D, Kiernan MC. Fatigue in multiple sclerosis: mechanisms and management. Clin Neurophysiol. 2010;121:809–817
16. Krupp LB, Serafin DJ, Christodoulou C. Multiple sclerosis-associated fatigue. Expert Rev Neurother. 2010;10:1437–1447
17. Bol Y, Duits AA, Hupperts RM, Vlaeyen JW, Verhey FR. The psychology of fatigue in patients with multiple sclerosis: a review. J Psychosom Res. 2009;66:3–11
18. Kos D, Duportail M, D’hooghe M, Nagels G, Kerckhofs E. Multidisciplinary fatigue management programme in multiple sclerosis: a randomized clinical trial. Mult Scler. 2007;13:996–1003
19. Minisola S, Pepe J, Piemonte S, Cipriani C. The diagnosis and management of hypercalcaemia. BMJ. 2015;350:h2723
20. Palmér M, Jakobsson S, Akerström G, Ljunghall S. Prevalence of hypercalcaemia in a health survey: a 14-year follow-up study of serum calcium values. Eur J Clin Invest. 1988;18:39-46
21. Gastanaga VM, Schwartzberg LS, Jain RK, et al. Prevalence of hypercalcemia among cancer patients in the United States. Cancer Med. 2016;5:2091-2100
22. Balasubramanian P, Majumdar SK. Albumin-corrected calcium and the prevalence and categories of hypercalcemia in hospitalized patients with 1-year follow-up of undiagnosed cases. Endocr Pract. 2021;27:279-285
23. Donovan Walker M, Shane E. Hypercalcemia, A review. JAMA 2022;328(16):1624-1636
24. Hewison M, Kantorovich V, Liker HR, et al. Vitamin D-mediated hypercalcemia in lymphoma: evidence for hormone production by tumor-adjacent macrophages. J Bone Miner Res. 2003;18:579-582
25. Beall DP, Scofield RH. Milk-alkali syndrome associated with calcium carbonate consumption: report of 7 patients with parathyroid hormone levels and an estimate of prevalence among patients hospitalized with hypercalcemia. Medicine (Baltimore). 1995;74:89-96
26. Machado MC, Bruce-Mensah A, Whitmire M, Rizvi AA. Hypercalcemia associated with calcium supplement use: prevalence and characteristics in hospitalized patients. J Clin Med. 2015;4:414-424
27. Griebeler ML, Kearns AE, Ryu E, et al. Thiazide-associated hypercalcemia: incidence and association with primary hyperparathyroidism over two decades. J Clin Endocrinol Metab. 2016;101:1166-1173
28. Carroll MF, Schade DS. A practical approach to hypercalcemia. Am Fam Physician. 2003;67:1959-1966
29. Sun Q, Zhang T, Chen P, Nan-Wei T, Zhang M. Glucose metabolic disorder in primary hyperparathyroidism: a systematic review and meta-analysis. Int J Clin Exp Med. 2019;12:11964-11973
30. Kalla A, Krishnamoorthy P, Gopalakrishnan A, Garg J, Patel NC, Figueredo VM. Primary hyperparathyroidism predicts hypertension: results from the National Inpatient Sample. Int J Cardiol. 2017;227:335-337
31. Minisola S, Arnold A, Belaya Z, et al. Epidemiology, pathophysiology, and genetics of primary hyperparathyroidism. J Bone Miner Res. 2022;37:2315-2329
32. El-Haji Fuleian G, Chakhtoura M, Cipriani C, et al. Classical and Nonclassical Manifestations of Primary Hyperparathyroidism. J Bone Miner Res. 2022;37:2330-2350

Most read articles by the same author(s)

1 2 3 4 > >>